QuidelOrtho Financial Ratios
NASDAQ: QDELHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
QuidelOrtho ratio analysis
QuidelOrtho earned a net margin of -41.5% in FY 2025, up from -73.7% a year earlier. Gross margin was 46.7% compared with a median of 59.3% over the prior 5 years. Return on equity reached -58.9%, meaning QuidelOrtho generated -0.59 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 1.38 versus 0.83 the year before, and the current ratio was 1.50. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
QuidelOrtho financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | 8.96 | 8.22 | 9.66 |
| Price / sales | 0.73 | 1.07 | 1.64 | 1.49 | 3.35 | 4.55 |
| Price / book | 1.03 | 1.00 | 0.98 | 0.99 | 2.95 | 5.68 |
| Gross margin | 46.7% | 46.2% | 49.9% | 59.3% | 75.3% | 81.6% |
| Operating margin | -33.7% | -70.5% | 4.6% | 25.8% | 53.3% | 63.8% |
| Net margin | -41.5% | -73.7% | -0.3% | 16.8% | 41.5% | 48.8% |
| Free cash flow margin | -3.0% | -4.0% | 2.4% | 22.8% | 30.2% | 34.0% |
| Return on equity (ROE) | -58.9% | -68.8% | -0.2% | 11.1% | 36.5% | 60.8% |
| Return on assets (ROA) | -19.6% | -31.9% | -0.1% | 6.2% | 29.0% | — |
| Debt / equity | 1.38 | 0.83 | 0.48 | 0.53 | 0.00 | — |
| Current ratio | 1.50 | 1.22 | 1.57 | 1.56 | 4.45 | — |
| Revenue growth | -1.9% | -7.2% | -8.2% | 92.3% | 2.2% | — |
| EPS growth | — | — | -101.6% | -41.8% | -11.7% | — |